These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20004697)

  • 1. Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats.
    Moriyama T; Kemi M; Okumura C; Yoshihara K; Horie T
    Toxicology; 2010 Jan; 268(1-2):89-97. PubMed ID: 20004697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated cardiac 3-deoxyglucosone, a highly reactive intermediate in glycation reaction, in doxorubicin-induced cardiotoxicity in rats.
    Moriyama T; Kemi M; Horie T
    Pathophysiology; 2016 Sep; 23(3):237-42. PubMed ID: 27514460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats.
    Waanders F; Greven WL; Baynes JW; Thorpe SR; Kramer AB; Nagai R; Sakata N; van Goor H; Navis G
    Nephrol Dial Transplant; 2005 Oct; 20(10):2060-70. PubMed ID: 15956058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.
    Horie K; Miyata T; Maeda K; Miyata S; Sugiyama S; Sakai H; van Ypersole de Strihou C; Monnier VM; Witztum JL; Kurokawa K
    J Clin Invest; 1997 Dec; 100(12):2995-3004. PubMed ID: 9399945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
    Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
    Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.
    Miyata T; Wada Y; Cai Z; Iida Y; Horie K; Yasuda Y; Maeda K; Kurokawa K; van Ypersele de Strihou C
    Kidney Int; 1997 Apr; 51(4):1170-81. PubMed ID: 9083283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
    Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of advanced glycation end products in human cataractous lenses.
    Franke S; Dawczynski J; Strobel J; Niwa T; Stahl P; Stein G
    J Cataract Refract Surg; 2003 May; 29(5):998-1004. PubMed ID: 12781289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of valsartan therapy on protein glycoxidation.
    Monacelli F; Poggi A; Storace D; Durante A; Traverso N; Viviani GL; Odetti P
    Metabolism; 2006 Dec; 55(12):1619-24. PubMed ID: 17142134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
    Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
    Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end-products in anterior chamber aqueous of cataractous patients.
    Franke S; Stein F; Dawczynski J; Blum M; Kubetschka U; Stein G; Strobel J
    J Cataract Refract Surg; 2003 Feb; 29(2):329-35. PubMed ID: 12648645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons.
    Horie K; Miyata T; Yasuda T; Takeda A; Yasuda Y; Maeda K; Sobue G; Kurokawa K
    Biochem Biophys Res Commun; 1997 Jul; 236(2):327-32. PubMed ID: 9240434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes.
    O'Connell JL; Romano MM; Campos Pulici EC; Carvalho EE; de Souza FR; Tanaka DM; Maciel BC; Salgado HC; Fazan-Júnior R; Rossi MA; Simões MV
    Exp Toxicol Pathol; 2017 Apr; 69(4):213-219. PubMed ID: 28153388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age.
    Handa JT; Verzijl N; Matsunaga H; Aotaki-Keen A; Lutty GA; te Koppele JM; Miyata T; Hjelmeland LM
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):775-9. PubMed ID: 10067983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
    Ghanem AA; Elewa A; Arafa LF
    Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
    Sugiyama T; Okuno T; Fukuhara M; Oku H; Ikeda T; Obayashi H; Ohta M; Fukui M; Hasegawa G; Nakamura N
    Exp Eye Res; 2007 Sep; 85(3):406-12. PubMed ID: 17678894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac troponin T and advanced glycation end-products in hemodialysis patients.
    Taki K; Tsuruta Y; Niwa T
    Am J Nephrol; 2008; 28(5):701-6. PubMed ID: 18431051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients.
    Nur E; Brandjes DP; Schnog JJ; Otten HM; Fijnvandraat K; Schalkwijk CG; Biemond BJ;
    Br J Haematol; 2010 Oct; 151(1):62-9. PubMed ID: 20678158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.
    Degenhardt TP; Fu MX; Voss E; Reiff K; Neidlein R; Strein K; Thorpe SR; Baynes JW; Reiter R
    Diabetes Res Clin Pract; 1999 Feb; 43(2):81-9. PubMed ID: 10221660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.